Investors

Welcome to Elicera's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders.

If you need more information or have any questions, please contact Jamal El-Mosleh, CEO.
‍
Phone: +46(0)703 31 90 51
Email: info@elicera.com

Press Releases

September 8, 2023
Regulatory
Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform
Read more
August 29, 2023
Regulatory
Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023
Read more
August 10, 2023
Regulatory
Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program
Read more
All Press Releases

Corporate Governance

The following sections contain information that are relevant for Elicera's corporate governance.

Articles of AssociationGeneral MeetingBoardManagementAuditorCertified Adviser

The Share

Elicera Therapeutics is listed on Nasdaq First North Growth Market. The company has issued one class of shares and the total number of shares amounts to 19 782 000.

Read about the Share

Financial Reports

Front cover of an Elicera report
Latest report:
August 29, 2023
Q2 report 2023
All Financial Reports

Financial Calendar

See the calendar

Analyst Coverage

Read the latest analysis on Elicera here:

Penser Future (in Swedish)
All analyses
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.